10x Genomics, Inc. (NASDAQ:TXG) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET
Company Participants
Adam S. Taich – CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
Cassie Corneau – Manager of Investor Relations & Strategic Finance
Serge Saxonov – Co-Founder, CEO & Director
Conference Call Participants
Daniel Anthony Arias – Stifel, Nicolaus & Company, Incorporated, Research Division
Jacob Krahenbuhl – William Blair & Company L.L.C., Research Division
Jaden Nyjai Rismay – JPMorgan Chase & Co, Research Division
Kyle Boucher – TD Cowen, Research Division
Kyle Alexander Mikson – Canaccord Genuity Corp., Research Division
Lu Li – UBS Investment Bank, Research Division
Madeline Kendall Mollman – Wolfe Research, LLC
Mason Owen Carrico – Stephens Inc., Research Division
Michael Leonidovich Ryskin – BofA Securities, Research Division
Patrick Bernard Donnelly – Citigroup Inc., Research Division
Salem Salem – Barclays Bank PLC, Research Division
Thomas VonDerVellen – Guggenheim Securities, LLC, Research Division
Operator
Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the 10x Genomics Second Quarter 2025 Earnings Conference Call. [Operator Instructions]
I would now like to turn the call over to Cassie Corneau, Investor Relations and Strategic Finance. Kathy. Cassie, please go ahead.
Cassie Corneau
Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the second quarter ended June 30, 2025. If you have not received this news release or would like to be added to the company’s distribution list, please send an e- mail to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company’s website, 10xgenomics.com, for at least 45 days following this call.
Before we begin, I’d like to remind you that management will
#10x #Genomics #TXG #Earnings #Call #Transcript